INDIANAPOLIS, IN – In a significant development, the Food and Drug Administration has granted approval to an Alzheimer’s drug developed by Eli Lilly. The drug, known as Kisunla, has been approved for the treatment of early symptomatic Alzheimer’s disease, making it one of the few treatments available that modify the underlying disease’s progression.

The decision by the FDA comes after a panel of independent experts unanimously endorsed the drug last month, highlighting the benefits of slowing the cognitive and functional decline associated with Alzheimer’s. Despite not halting the disease, Kisunla has shown promise in slowing down its progression, offering hope to the millions of Americans affected by this devastating condition.

Eli Lilly’s chief scientific officer, Daniel Skovronsky, expressed optimism about Kisunla, describing it as a significant milestone in the battle against Alzheimer’s. The drug works by clearing amyloid beta, a sticky plaque in the brain linked to the disease, showcasing its potential to modify the course of Alzheimer’s.

While the approval of Kisunla is a step forward in Alzheimer’s treatment, the drug has not been without controversy. Concerns have been raised about the risks and benefits associated with the drug, with some critics questioning the modest benefits it offers. However, the FDA has signaled confidence in the drug’s safety profile, aligning it with other amyloid-targeting medications.

The cost of Kisunla will vary by patient, with a six-month course of therapy estimated to cost $12,522. Medicare is expected to cover the treatment for certain patients, easing the financial burden on those in need. Additionally, Eli Lilly is exploring the possibility of using Kisunla to prevent Alzheimer’s in patients without symptoms, showcasing the drug’s potential for broader applications.

Overall, the approval of Kisunla marks a significant success for Eli Lilly and provides hope for individuals and families affected by Alzheimer’s. The drug’s ability to modify the course of the disease offers a glimmer of hope in the fight against Alzheimer’s, underscoring the importance of continued research and innovation in the healthcare industry.